BENITIONSClinical Trial Intelligence

Pharmacokinetics Study of Oral 2-Deoxy-D-Glucose (2DG) in Subjects With a Confirmed Diagnosis of Epilepsy

Фаза 2 Завершено NCT05605301

ЗаболеваниеEpilepsy; Seizure
ФазаФаза 2
СпонсорUniversity of Virginia
СтатусЗавершено
Участники9 участн.
ВмешательствоOral 2-Deoxy-D-Glucose (2DG)
Дата начала2.09.2022
Дата завершения5.02.2024
Публикация результатов9.06.2026

Кратко

This project studies how 2-deoxy-glucose (2DG) pills are absorbed and distributed in people with epilepsy. 2DG is similar to glucose, the main energy source for the brain, but it cannot be used as energy. During seizures, neurons are at a very high metabolic state with huge glucose metabolism as glycolysis is accelerated to supply the high metabolic needs of a seizure. 2DG is taken up by cells but cannot be metabolized by the first enzyme in the glycolytic pathway, thus is stops, or "clogs up", glycolysis. Since brain metabolism is almost entirely dependent on glucose as an energy source, glycolysis is arrested and may stop seizures. It is hoped that 2DG will stop seizures by interfering with the brain's energy use. This is an open-label phase 2 study of the pharmacokinetics (PK), safety, and tolerability of 2DG administered orally to adult epilepsy patients. A 3-level 2DG dose escalation is planned in sequential cohorts of 3 subjects in each cohort with review of each cohort before proceeding to the next cohort. On the day of oral 2DG exposure, subjects will receive a single dose of 40 mg in the first cohort, a single dose of 60 mg in the second cohort, and two 60 mg doses (60 mg

Area Under the Curve From Time Zero to Last Observed Time Point (AUClast)

From time of drug administration until 24 hours post-dose · hour*ug/mL

2DG 40 mg Single Dose2.81 ± 0.49 hour*ug/mL
2DG 60 mg Single Dose2.93 ± 1.13 hour*ug/mL
2DG 60 mg Twice Daily4.16 ± 0.57 hour*ug/mL

Area Under the Curve From Time Zero Extrapolated to Infinity (AUCinf)

From time of drug administration until 24 hours post-dose · hr*ug/mL

2DG 40 mg Single Dose3.56 ± NA hr*ug/mL
2DG 60 mg Single Dose3.19 ± 1.59 hr*ug/mL
2DG 60 mg Twice Daily4.71 ± 0.81 hr*ug/mL

Открыть в BENITIONS Открыть на ClinicalTrials.gov

Другие исследования по этому заболеванию

Все исследования

Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.